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A pre-debate vote showed the audience to be overwhel-
mingly in favour of the motion.
Dr Per Lønning spoke in favour. He made the point that
tailormade therapy should not be confused with implementing
simple prognostic or predictive factors that in general do not
define direct biological targets but rather should implement
biological parameters revealing a variable statistical corre-
lation to outcome. He discussed that breast cancers have
recently been separated into five distinct classes based on
gene expression profiles: luminal A, luminal B, HER2, basal
class, and, finally, so-called normal breast-like tumours. Dr
Lønning argued that the identification of oestrogen receptor
as a predictive marker has made endocrine therapy in breast
cancer the ultimate targeted or tailored cancer therapy. Over
the past decade, tailored therapy with the use of anti-HER2
strategies has revolutionised treatment for around 20% of
cancer patients. The introduction of poly(ADP-ribose)
polymerase inhibitors has improved the process of tailoring
treatment for patients carrying BRCA1 and BRCA2 defect
tumours, and probably also for many additional patients
carrying triple-negative tumours. His argument was that the
results achieved up to now suggest that tailored therapy for
most if not all breast cancer patients in need of systemic
treatments is a realistic approach in the near future.
Dr Kathy Pritchard then spoke against the motion. She like-
wise acknowledged the role of oestrogen receptor and HER2
in targeted therapy, and further discussed gene expression
arrays such as OncotypeDX for targeting treatment. She
went on to caution against so-called predictive factors for
specific chemotherapies including HER2 and topoisomerase
IIα, demonstrating that their role so far is uncertain given the
inconsistency of individual studies addressing the issue. She
concluded that neither of these markers were ready for use
and that methodologic issues remained, including lack of
reproducibility of measurements, publication bias and lack of
power of individual studies. She agreed that the motion was
laudable in principle but argued that more research was
needed.
At the conclusion of the debate, the majority of the audience
still supported the motion but a significant minority switched
their vote against. Both Dr Lonning and Dr Pritchard could
therefore be said to have won.
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